Breakthrough prize 2026 honors pioneers of first CRISPR therapy for blood disorders
San Francisco: The Breakthrough Prize Foundation announced its 2026 laureates on April 18, awarding six prizes of $3 million each across life sciences, fundamental physics, and mathematics. The total purse this year reached $18.75 million.
Stuart Orkin and Swee Lay Thein shared one of the three life sciences prizes for their work that transformed treatment for sickle cell disease and beta-thalassemia, two deadly inherited blood disorders affecting millions worldwide.
Their research uncovered how the body switches between fetal and adult hemoglobin. That discovery laid the scientific groundwork for Casgevy, the first CRISPR-based medicinal treatment approved anywhere in the world for any disease. Casgevy works by editing patients’ own blood stem cells to restore healthy hemoglobin production, offering a functional cure for conditions that previously required lifelong transfusions or had limited options.
The award recognizes decades of fundamental research translating into real-world therapy. For patients and families impacted by these disorders, the prize highlights a milestone moment where basic biology became a life-changing medicine.
The Breakthrough Prizes, often called the “Oscars of Science,” celebrate achievements with profound impact on human knowledge and health. Orkin and Thein’s recognition underscores how understanding disease mechanisms at the molecular level can unlock entirely new classes of treatment.
